Corporate Publications

Reflecting on another busy year across the clinical trials sector, there are many reasons to feel confident about Australia’s position in the global healthcare ecosystem and specifically, the clinical trials discipline.

The Australian clinical trials landscape has thrived in 2024-2025.

This has been supported by a renewed commitment from the Commonwealth in the development of a National Health and Medical Research Strategy, the continued development of the National One Stop Shop program, refinement and further embedding of the National Clinical Trial Governance Framework, ongoing reviews of
funding programs, and an ambition to improve alignment across policies and initiatives to ensure equity, access and patient outcomes are front and centre of decision making.

This national approach has been further complemented by Jurisdiction based programs and priorities, which also support the unique communities they operate in.

The clinical trial workforce maintained their momentum to create change, our industry colleagues continued to advocate for innovation through collaboration, and health care providers doubled down on efforts to bring evidence front and centre in patient care, despite challenging financial times.

This year ACTA have continued to facilitate communities of practice, delivered a range of education, collaboration and networking opportunities, advocated for our members, acted as the voice for the clinical trials sector, developed
resources, and led initiatives to support the delivery and effectiveness of clinical trials in Australia.

As your national peak body, ACTA are proud of the positive impact our activities have had on the clinical trials sector.

Prof Christopher Reid
ACTA Chair